TransMedics Group, Inc. — Director's Dealing 2022

Dec 5, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TransMedics Group, Inc. (TMDX)
CIK: 0001756262
Period of Report: 2022-12-01

Reporting Person: Gordon Stephen (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-01	Common Stock	M	10000	$16.14	Acquired	15714	Direct
2022-12-01	Common Stock	S	9969	$61.30	Disposed	5745	Direct
2022-12-01	Common Stock	S	31	$62.15	Disposed	5714	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-12-01	Stock Option (Right to Buy)	$16.14	M	10000	Disposed	2030-02-27	Common Stock (10000)	Direct

Footnotes

F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $61.05 to $62.04, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $62.10 to $62.15, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 27, 2024.